companion anim momentum remain strong
manag expect livestock rebound start
tweak model estim remain larg
zoeti post solid quarter despit substanti weak livestock
management expect recoveri livestock rest year management execut
well oper companion anim strength fulli off-set livestock
fx headwind challeng macro backdrop declin african
swine fever outbreak china importantli management remain confid
livestock return growth full year specif ceo ramon
state expect poultri grow line slightli ahead
market term swine expect go lower market mainli
african swine fever expect temporari impact
mayb third fourth quarter definit expect economi
recoveri mani market outsid china expand product
gener signific growth cattl also expect year overal
innov engin remain strong pipelin updat watch zoeti receiv
approv apoquel china one zoeti largest companion anim
market management expect launch product within next two
month anticip launch year new injector parasiticid
formul protect dog heartworm month pend
fda approv simparica trio remain track launch current
still regulatori review european medicin agenc
review also underway canada brazil submiss
expect japan china australia year zoeti still work new
monoclon antibodi timelin undisclos manag pain dog cat
dermatolog cat management also state earn call
program companion anim livestock support growth
also confid pipelin
maintain growth line faster market
tweak model estim remain larg unchang
tweak revenu project follow
ep estim remain larg unchang
model compound-annual-growth-rate revenu ep
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
base case ep current price-to-earnings premium
vs also roughli line w/ average sinc ipo project
bull case ep
bull case ep
new product upsid drive faster revenu growth project zoeti
pursu value-enhanc organ ep upsid plu upsid
yield ep forecast
base case ep
base case ep
project low double-digit ep growth driven growth key
companion anim derm product project compound-annual-growth-rate revenu growth
ep compound-annual-growth-rate larger intern market share growth
beyond global roll-out new product give us confid
project
bear case ep
bear case ep
fda delay approv simparica trio face lower end-market growth
greater competit pressur drive weak financi result fda
approv simparica trio zoeti miss ep estimate price-to-earnings multipl
zoeti combin compel
convers tuck-in option
drive out-performance
ep growth
top-lin growth oper margin
livestock rev demand
meat milk project least doubl
next year due larg part
popul growth increas
affluenc emerg market
companion anim rev
global spend pet grow
quarterli result guidanc updat
new product ramp rel
zoeti becom activ deploy
capit acquir products/compani
competitor perform better/wors
risk achiev price
long-term margin expans fail
new govern regul legisl
impact growth
dollar strength rel foreign
exhibit consensu ntm price-to-earnings vs spec pharma average continu trade larg
premium group
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
